USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Galderma Research & Development

USPTO PatentsView assignee record - 107 granted patents across 33 technology areas, active 2015–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

107

Total patents granted

CPC technology areas

18.5

Avg claims per patent

-47%

5-year filing velocity

The verdict

Galderma holds 107 US patents across 33 technology areas, rank #3,452 of 50,000 tracked assignees.

#3,452
of 50,000 US assignees by volume: Top 16%
by Innovation Score (48.9/100): 18.5
avg claims per patent: -47%
filing velocity, last 5 yrs

Portfolio overview

Galderma Research & Development has been granted 107 US utility patents between 2015 and 2023, placing Galderma Research & Development at rank #3,452 across all assignees tracked by PlainPatent. This portfolio spans 33 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Galderma Research & Development is one of the more focused assignees in the PatentsView dataset. By volume, Galderma sits between Costa Del Mar, Inc. (107 patents, rank #3,448) and Ohio University (107 patents, rank #3,456) - the closest US assignees by grant volume. The composite Innovation Score of 48.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 37 grants, compared with 70 in the 2015–2019 window, a -47% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Galderma Research & Development's 18.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 33 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Galderma Research & Development against peers pursuing similar technology classes.

Costa Del Mar

107
Cylance

107
Diebold Nixdorf I…

107
Elbit Systems

107
Jilin University

107
Mitsui High-tec

107
Nxgen Partners IP

107
Ohio University

107
Galderma Research… ◀

107

What this shows Galderma holds 107 patents at rank #3,452, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Galderma

By rank, the assignees closest to #3,452 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Galderma's primary technology class.

Galderma's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Galderma Research & Development patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	18	16.8%
2016	19	17.8%
2017	9	8.4%
2018	12	11.2%
2019	12	11.2%
2020	18	16.8%
2021	11	10.3%
2022	6	5.6%
2023	2	1.9%

Which technologies does Galderma Research & Development patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 84

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 73

C07D - HETEROCYCLIC COMPOUNDS 38

A61Q - SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS 37

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 13

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 8

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 5

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 5

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 4

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 3

B65D - CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES 3

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 3

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 2

G01F - MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME 2

C07K - PEPTIDES 2

Top 15 of 33 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#3,452

Across all tracked assignees

Innovation Score

48.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Galderma Research & Development hold?

Galderma Research & Development holds 107 US granted patents filed between 2015 and 2023, spanning 33 technology areas.

What is Galderma Research & Development's Innovation Score?

Galderma Research & Development has an Innovation Score of 48.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Galderma Research & Development focus on?

Galderma Research & Development's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 84 patents. The company has filed patents in 33 CPC subclasses total.

Is Galderma Research & Development's patent filing rate increasing or decreasing?

Galderma Research & Development's recent filing velocity is -47% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Galderma Research & Development's patents?

Galderma Research & Development's patents average 18.5 claims each. This falls within the standard range, providing solid legal coverage.

How is the Galderma Research & Development patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Galderma's 107 grants land it in the top 16% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Galderma ranks #3,452 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.